%0 Journal Article
%T Real-world dosing patterns of regorafenib for patients with metastatic colorectal cancer in Spain: the RE-SEARCH study.
%A López Muñoz AM
%A González Flores E
%A Carral Maseda A
%A Pimentel Cáceres P
%A Afonso Gómez R
%A López López C
%A Jimeno Maté R
%A Reina Zoilo JJ
%A Castañón López C
%A Salgado Fernández M
%A Aparicio Urtasun J
%A Asensio Martínez E
%A Martín Gómez T
%J Clin Transl Oncol
%V 0
%N 0
%D 2024 Aug 11
%M 39127984
%F 3.34
%R 10.1007/s12094-024-03630-1
%X <B>OBJECTIVE: </B>To describe the dosing patterns of regorafenib in a real-world population of patients with metastatic colorectal cancer (mCRC) in a routine clinical practice setting in Spain, focusing on the starting dose of regorafenib.<BR><B>METHODS: </B>An observational, retrospective, multicenter study that included patients ≥ 18 years old who had histologically documented mCRC and who had initiated treatment with regorafenib since January 2017. Post hoc categorization of dosing patterns revealed the following: initial dose < 160 mg and dose escalation, initial dose < 160 mg and maintenance, initial dose equal to 160 mg and maintenance, and initial dose equal to 160 mg and dose reduction.<BR><B>RESULTS: </B>Most patients (152/241, 63.8%) initiated treatment with regorafenib at doses < 160 mg. There was large variation in the starting dose of regorafenib over time: in 2017, most patients (59%) initiated regorafenib at a dose of 160 mg, this proportion decreased to 6% in 2021. There were no significant differences in the median progression-free survival according to the regorafenib dose patterns during the first two cycles. The proportion of patients who reported at least one adverse event (AE), had a grade 3-4 AE or had an AE leading to dose reduction was greater in the group of patients who received an initial dose equal to 160 and reduction.<BR><B>CONCLUSIONS: </B>Our results indicate that physicians in Spain have gradually adopted a dose-escalation approach during cycle 1, which is a common practice for starting treatment with a reduced dose (< 160 mg/day), a strategy that seems to improve tolerability while maintaining efficacy.<BR><B>BACKGROUND: </B>Not applicable.